Immune Modulation by Androgen Deprivation and Radiation Therapy: Implications for Prostate Cancer Immunotherapy
Open Access
Abstract
Prostate cancer patients often receive androgen deprivation therapy (ADT) in combination with radiation therapy (RT). Recent evidence suggests that both ADT and RT have immune modulatory properties. First, ADT can cause infiltration of lymphocytes into the prostate, although it remains unclear whether the influx of lymphocytes is beneficial, particularly with the advent of new classes of androgen blockers. Second, in rare cases, radiation can elicit immune responses that mediate regression of metastatic lesions lying outside the field of radiation, a phenomenon known as the abscopal response. In light of these findings, there is emerging interest in exploiting any potential synergy between ADT, RT, and immunotherapy. Here, we provide a comprehensive review of the rationale behind combining immunotherapy with ADT and RT for the treatment of prostate cancer, including an examination of the current clinical trials that employ this combination. The reported outcomes of several trials demonstrate the promise of this combination strategy; however, further scrutiny is needed to elucidate how these standard therapies interact with immune modulators. In addition, we discuss the importance of synchronizing immune modulation relative to ADT and RT, and provide insight into elements that may impact the ability to achieve maximum synergy between these treatments.Keywords
This publication has 165 references indexed in Scilit:
- Destructive impact of t-lymphocytes, NK and mast cells on basal cell layers: implications for tumor invasionBMC Cancer, 2013
- Androgen Receptor Influences on Body Defense System via Modulation of Innate and Adaptive Immune SystemsThe American Journal of Pathology, 2012
- Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trialThe Lancet, 2011
- Prostate cancer patients on androgen deprivation therapy develop persistent changes in adaptive immune responsesHuman Immunology, 2010
- B-cell-derived lymphotoxin promotes castration-resistant prostate cancerNature, 2010
- Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancerCancer Immunology, Immunotherapy, 2009
- Association of HLA class I antigen abnormalities with disease progression and early recurrence in prostate cancerCancer Immunology, Immunotherapy, 2009
- Androgen ablation augments prostate cancer vaccine immunogenicity only when applied after immunizationThe Prostate, 2009
- How regulatory T cells workNature Reviews Immunology, 2008
- Radiotherapy augments the immune response to prostate cancer in a time‐dependent mannerThe Prostate, 2008